Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Revance Therapeutics, Inc. (RVNC)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | 201.8% | 206.3% | 321.1% | 471.0% | 582.8% | 753.0% |
| Gross profit | | | -101.8% | -106.3% | -221.1% | -371.0% | -482.8% | -653.0% |
| Selling, general and administrative | | | 188.9% | 193.4% | 217.1% | | 325.8% | 426.2% |
| Research and development | | | 102.4% | 116.0% | 133.4% | 149.4% | 185.1% | 245.6% |
| General and administrative | | | | | | 59.7% | | |
| EBITDA | | | -217.6% | -233.4% | -273.9% | -327.5% | -432.3% | -590.7% |
| Depreciation | | | 21.0% | 22.7% | 23.4% | 25.5% | 29.8% | 36.9% |
| EBIT | | | -238.6% | -256.1% | -297.3% | -353.1% | -462.1% | -627.7% |
| Pre-tax income | | | -251.9% | -265.0% | -305.3% | -361.6% | -475.3% | -650.6% |
| Income taxes | | | -0.6% | 0.0% | 0.0% | 0.0% | -0.3% | -0.4% |
| Net income | | | -251.9% | -265.0% | -305.3% | -361.6% | -470.8% | -644.6% |
|